Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2

NCT03908749 ·Status: UNKNOWN

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

NCT06700369 ·Status: RECRUITING

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

NCT03854617 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

NCT04158505 ·Status: UNKNOWN

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

NCT06495541 ·Status: NOT_YET_RECRUITING ·Phase: NA

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

NCT05149014 ·Status: COMPLETED

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

NCT06722612 ·Status: RECRUITING

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

NCT07180056 ·Status: RECRUITING

A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy

NCT06470347 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

NCT06711055 ·Status: RECRUITING

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

NCT05295043 ·Status: UNKNOWN ·Phase: NA

Study of TFX06 in Women With Advanced Breast Cancer.

NCT05927779 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

NCT05525767 ·Status: RECRUITING ·Phase: PHASE4

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT05561686 ·Status: UNKNOWN

Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study

NCT05231863 ·Status: UNKNOWN

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

NCT07129187 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

NCT06548919 ·Status: RECRUITING

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

NCT06914661 ·Status: ENROLLING_BY_INVITATION

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

NCT05918328 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

NCT05945927 ·Status: COMPLETED

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

NCT03084939 ·Status: COMPLETED ·Phase: PHASE3

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2